HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 ...

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery.

Launched in 2012, the multinational KATHERINE trial involved almost 1,500 women with HER2-positive breast cancer and residual disease in the breast or axillary lymph nodes after neoadjuvant ...

The KATHERINE trial included 1,486 patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer who had residual invasive disease in the breast or axillary lymph node ...

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer: Final 10-Year Analysis of the Open-Label, Single-Arm, Phase 2 APT Trial Trastuzumab Emtansine for Residual ...

HER2-positive breast cancer ... However, if a patient still has cancer cells at the time of surgery or residual cancer are identified after surgery, there are additional treatment options available to ...

An early-stage HER2-positive (HER2+) breast cancer is always a shock, but today’s treatment options should give you hope. Over the past 2 decades, advances in medicine have brought us new ...

Baseline ctDNA presence linked to larger tumors and higher residual cancer burden scores in HR-positive ... The phase 2 PELOPS trial included 49 patients with stages 1 to 3 HR-positive, HER2-negative ...